Alveolar hemorrhage associated with pemetrexed administration

Intern Med. 2015;54(7):833-6. doi: 10.2169/internalmedicine.54.3414. Epub 2015 Apr 1.

Abstract

We herein describe a 67-year-old man with advanced adenocarcinoma of the lung who developed an alveolar hemorrhage (AH) associated with pemetrexed. He received four courses of pemetrexed therapy with carboplatin and seven courses of pemetrexed maintenance therapy. One week after the last pemetrexed administration, the patient developed hemoptysis with deteriorating dyspnea and anemia. Chest images showed diffuse ground-glass attenuation. The diagnosis of AH was based on findings of bloody bronchoalveolar lavage (BAL) fluid, hemosiderin-laden macrophages in the BAL fluid, and a transbronchial lung biopsy sample. This report is the first to describe AH associated with pemetrexed.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy
  • Anemia / chemically induced
  • Antimetabolites, Antineoplastic / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bronchoalveolar Lavage Fluid
  • Carboplatin / administration & dosage
  • Dyspnea / chemically induced
  • Glutamates / adverse effects*
  • Guanine / adverse effects
  • Guanine / analogs & derivatives*
  • Hemoptysis / chemically induced
  • Hemorrhage / chemically induced*
  • Hemorrhage / pathology
  • Humans
  • Lung Diseases / chemically induced*
  • Lung Diseases / pathology
  • Lung Neoplasms / drug therapy
  • Male
  • Middle Aged
  • Pemetrexed
  • Pulmonary Alveoli*
  • Tomography, X-Ray Computed

Substances

  • Antimetabolites, Antineoplastic
  • Glutamates
  • Pemetrexed
  • Guanine
  • Carboplatin